Protein Sciences To Begin Selling Novel Flu Vaccine; Flublok Has Virus-Free Appeal
This article was originally published in The Pink Sheet Daily
Executive Summary
The trivalent vaccine can be produced much faster than traditional vaccines and could be modified to compete with quadrivalent formulations.
You may also be interested in...
CBER New Biologic Tally Healthy In 2013, But For Innovation Look To 2014
Coagulation factors dominated the biologics center’s approvals in 2013, a solid year with eight novel BLAs cleared. Innovation level of 2013 CBER approvals was unremarkable, but first quarter of 2014 holds potential for advances in hemophilia and allergy treatment.
CBER New Biologic Tally Healthy In 2013, But For Innovation Look To 2014
Coagulation factors dominated the biologics center’s approvals in 2013, a solid year with eight novel BLAs cleared. Innovation level of 2013 CBER approvals was unremarkable, but first quarter of 2014 holds potential for advances in hemophilia and allergy treatment.
Flu Vaccines Likely To Remain Immune From Comparative Effectiveness
CDC’s Advisory Committee on Immunization Practices adds four recently-approved flu vaccines to its recommended list of products, but the committee chair expresses doubt that there could ever be data to make preferential recommendations.